hydroxychloroquine has been researched along with Thromboembolism in 26 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind, randomized trial of orally administered hydroxychloroquine sulphate in the prevention of venous thromboembolism after elective surgery on the hip, the drug or a placebo was given to fifty consecutive patients." | 9.04 | Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. ( Ainsworth, ME; Bowcock, SA; Cooke, ED; Dawson, MH; Ibbotson, RM; Pilcher, MF, 1977) |
| "Evidence for the usefulness of hydroxychloroquine as prophylaxis against thromboembolism after total hip replacement is examined." | 8.77 | Hydroxychloroquine and postoperative thromboembolism after total hip replacement. ( Loudon, JR, 1988) |
| "In a double-blind, randomized trial of orally administered hydroxychloroquine sulphate in the prevention of venous thromboembolism after elective surgery on the hip, the drug or a placebo was given to fifty consecutive patients." | 5.04 | Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. ( Ainsworth, ME; Bowcock, SA; Cooke, ED; Dawson, MH; Ibbotson, RM; Pilcher, MF, 1977) |
| "Evidence for the usefulness of hydroxychloroquine as prophylaxis against thromboembolism after total hip replacement is examined." | 4.77 | Hydroxychloroquine and postoperative thromboembolism after total hip replacement. ( Loudon, JR, 1988) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| "(1) Hydroxychloroquine has a possible anti-thrombotic action." | 2.38 | The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. ( Linker-Israeli, M; Metzger, AL; Stecher, VJ; Wallace, DJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (69.23) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Takeda, K | 1 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Sayer, G | 1 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 1 |
| Uriel, N | 1 |
| Masoumi, A | 1 |
| Di Perri, G | 1 |
| Faden, YA | 1 |
| Alghilan, NA | 1 |
| Alawami, SH | 1 |
| Alsulmi, ES | 1 |
| Alsum, HA | 1 |
| Katib, YA | 1 |
| Sabr, YS | 1 |
| Tahir, FH | 1 |
| Bondagji, NS | 1 |
| Alser, O | 1 |
| Mokhtari, A | 1 |
| Naar, L | 1 |
| Langeveld, K | 1 |
| Breen, KA | 1 |
| El Moheb, M | 1 |
| Kapoen, C | 1 |
| Gaitanidis, A | 1 |
| Christensen, MA | 1 |
| Maurer, LR | 1 |
| Mashbari, H | 1 |
| Bankhead-Kendall, B | 1 |
| Parks, J | 1 |
| Fawley, J | 1 |
| Saillant, N | 1 |
| Mendoza, A | 1 |
| Paranjape, C | 1 |
| Fagenholz, P | 1 |
| King, D | 1 |
| Lee, J | 1 |
| Farhat, MR | 1 |
| Velmahos, GC | 1 |
| Kaafarani, HMA | 1 |
| Metjian, A | 1 |
| Lim, W | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Bouchier-Hayes, D | 1 |
| Verstraete, M | 1 |
| Turpie, AG | 1 |
| Wallace, DJ | 3 |
| Linker-Israeli, M | 1 |
| Metzger, AL | 1 |
| Stecher, VJ | 1 |
| Cooke, ED | 1 |
| Dawson, MH | 1 |
| Ibbotson, RM | 1 |
| Bowcock, SA | 1 |
| Ainsworth, ME | 1 |
| Pilcher, MF | 1 |
| Kher, A | 1 |
| Toulemonde, F | 1 |
| Uhl, JF | 1 |
| Huguier, M | 1 |
| Hirsh, J | 5 |
| Dettori, AG | 1 |
| Pini, M | 1 |
| Quintavalla, R | 1 |
| Harker, LA | 2 |
| Gent, M | 3 |
| Genton, E | 3 |
| Gallus, AS | 1 |
| Pilcher, DB | 1 |
| Loudon, JR | 1 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Fuster, V | 1 |
| Bounameaux, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-ventilated Prone Positioning in the COVID-19 Population[NCT05957588] | 216 participants (Actual) | Interventional | 2021-10-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for hydroxychloroquine and Thromboembolism
| Article | Year |
|---|---|
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?
Topics: Adult; Anticoagulants; Aspirin; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medic | 2009 |
[Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
Topics: Anticoagulants; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Flurbiprof | 1980 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Topics: Animals; Antimalarials; CD8 Antigens; Humans; Hydroxychloroquine; Hypercholesterolemia; Interleukin- | 1993 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Topics: Antimalarials; Antiphospholipid Syndrome; Autoimmune Diseases; Chloroquine; Controlled Clinical Tria | 1996 |
[Prevention of postoperative thrombo-embolic complications. The principal methods, other than low-dose heparin].
Topics: Anticoagulants; Dextrans; Dipyridamole; Femoral Neck Fractures; Heparin; Hip Joint; Humans; Hydroxyc | 1977 |
[Prevention of thrombosis and embolism in digestive surgery].
Topics: Anticoagulants; Aspirin; Coumarins; Dextrans; Digestive System Surgical Procedures; Dipyridamole; He | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
[Treatment with antiplatelet drugs. Current status of knowledge].
Topics: Aspirin; Blood Platelet Disorders; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dextrans | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
Hydroxychloroquine and postoperative thromboembolism after total hip replacement.
Topics: Biomechanical Phenomena; Hip Prosthesis; Humans; Hydroxychloroquine; Pulmonary Embolism; Thromboembo | 1988 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
6 trials available for hydroxychloroquine and Thromboembolism
| Article | Year |
|---|---|
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations.
Topics: Administration, Oral; Aged; Arthroplasty; Body Weight; Clinical Trials as Topic; Double-Blind Method | 1977 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts).
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; Fibrin | 1975 |
9 other studies available for hydroxychloroquine and Thromboembolism
| Article | Year |
|---|---|
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infectio | 2020 |
Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019.
Topics: Anticoagulants; Antiviral Agents; Betacoronavirus; Congenital Abnormalities; Coronavirus Infections; | 2020 |
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.
Topics: Acute Kidney Injury; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Boston; Comorbidity | 2021 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |
The prevention of postoperative venous thromboembolism.
Topics: Anticoagulants; Aspirin; Dextrans; Heparin; Humans; Hydroxychloroquine; Leg; Postoperative Complicat | 1978 |
Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients.
Topics: Hematocrit; Humans; Hydroxychloroquine; Platelet Aggregation; Postoperative Complications; Surgical | 1975 |
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Thrombo | 1987 |
[Clinical use of anti-aggregative agents].
Topics: Aspirin; Dipyridamole; Humans; Hydroxychloroquine; Platelet Adhesiveness; Thromboembolism; Thromboph | 1973 |